A Phase 2, Randomized, Double-BLInd, Placebo- Controlled Study of UBEnimex in Patients With Pulmonary ARTerial HYpertension (WHO Group 1) (LIBERTY)
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Ubenimex (Primary)
- Indications Pulmonary arterial hypertension
- Focus Proof of concept; Therapeutic Use
- Acronyms LIBERTY
- Sponsors Eiger BioPharmaceuticals
- 02 Mar 2018 Status changed from active, no longer recruiting to completed.
- 16 Jan 2018 According to an Eiger BioPharmaceuticals media release, the company will discontinue the development of ubenimex in pulmonary arterial hypertension based on the results of this trial.
- 16 Jan 2018 Primary endpoint (Change in pulmonary vascular resistance (PVR)) has not been met according to an Eiger BioPharmaceuticals media release.